News Release

56 percent of Saudi Arabian women never had a cervical cancer screening test | BGI Insight

55.8% of Saudi Arabian women never had a screening test, higher than the global average of 31.2%

Reports and Proceedings

BGI Genomics

BGI Genomics Global 2023 State of Cervical Cancer Awareness Report

image: BGI Genomics Global 2023 State of Cervical Cancer Awareness Report view more 

Credit: BGI Genomics

Only 19% of Saudi Arabian women are diagnosed at stage I of cervical cancer where survival rates are highest, according to a study published by the King Abdulaziz University. To further motivate action to combat cervical cancer, BGI Genomics today released its State of Cervical Cancer Awareness Report in Saudi Arabia. This report assesses the level of knowledge, attitudes, and practices related to cervical cancer screening and HPV vaccination. By examining these key areas, this survey seeks to highlight the associated barriers and opportunities. 1,878 female respondents from six countries and regions were surveyed: Brazil, the Chinese mainland, Saudi Arabia, Serbia, Thailand, and Uruguay.

55.8% of Saudi Arabian women never had a screening test, higher than the global average of 31.2%. In addition, 64.1% of young Saudi Arabian women aged 21 to 25 years old are deterred by meeting a male doctor performing a pap smear. This ranks first among the six countries in this study in both categories. Therefore, there is an urgent need to offer HPV DNA tests to women, especially young women, in addition to pap smear tests. 

Other key takeaways from the report include:

HPV awareness affects cervical cancer screening rates: Among women who are unaware cervical cancer is often caused by HPV, 39.1% of them never undertaken cervical cancer screening which is higher than the global average of 31.2%.

Vaccination and screening form a virtuous cycle: For women who had the HPV vaccine, 82.1% had a cervical cancer screening, significantly higher than 60.6% of unvaccinated women. For women who had undergone screening, 45.8% received the HPV vaccine, which is higher relative to 22.1% of unscreened women. Informing women who missed national vaccination programs about where and when they could get vaccinated and screened is vital.

"Early cervical cancer detection is vital to save lives and eventually eliminate this dreaded disease in line with WHO's global strategy," said Zhang Lin, BGI Genomics Senior Product Manager. "This study shows increased awareness of women could be the missing link to boost vaccination and screening rates further."

To read and view country or region-level comparisons, please see link to access the full BGI Genomics State of Cervical Cancer Awareness Report 2023.

About BGI Genomics

BGI Genomics, headquartered in Shenzhen, China, is the world's leading integrated solutions provider of precision medicine. In July 2017, as a subsidiary of BGI Group, BGI Genomics (300676.SZ) was officially listed on the Shenzhen Stock Exchange.

The CE-certified SENTIS™ HPV test combines self-sampling technology and genotyping assay to detect 14 most important, "high-risk" types of HPV, including HPV -16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68 and 2 "low-risk" types of the virus, HPV -6, 11. HPV genotyping detection is based on Next Generation Sequencing (NGS) technology based on a large sample volume for each run, which decreases the testing cost for each individual. The WHO recommends DNA testing as a first-choice screening method for cervical cancer prevention.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.